T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

Aude G. Chapuis, Daniel Egan, Merav Bar, +21

Nature Medicine

Cell TherapyTransplantationT-regulatory CellImmunologyAutoimmunity +5

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Farhad Ravandi, Asad Bashey, Wendy Stock, +10

Blood

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Susan Bal, Myo Htut, Omar Nadeem, +17

Blood

Targeting an alternate Wilms’ tumor antigen 1 peptide bypasses immunoproteasome dependency

Miranda C. Lahman, Thomas M. Schmitt, Kelly G. Paulson, +27

Science Translational Medicine

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji Kumar, Melissa Alsina, Betsy LaPlant, +10

Blood

Hematological MalignancyAscent TrialMedicineMetronomic TherapyHematology +7

Variants in hormone biosynthesis genes and risk of endometrial cancer

Sara H. Olson, Irene Orlow, Sharon Bayuga, +13

Cancer Causes & Control

Somatic VariantGeneticsHormone Biosynthesis GenesGynecologyCancer Genetics +3

Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

H. Joachim Deeg, Emily A. Stevens, Rachel B. Salit, +18

Biology of Blood and Marrow Transplantation

Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation

Daniel Egan, Lan Beppu, Jerald P. Radich

Biology of Blood and Marrow Transplantation

Mixed-phenotype Acute LeukemiaImmunologyPathologySame MutationPhiladelphia-positive Leukemia +17

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Susan Bal, Larry D. Anderson, Omar Nadeem, +17

Blood

S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY

Susan Bal, Jesús G. Berdeja, Myo Htut, +14

HemaSphere

Cell TherapyMember DImmunologyImmune RegulationImmunoediting +19